Fig 2: Plasma CTAPIII/CXCL7 concentration in lung cancer patients and healthy controls. Panels A, training set; B, test set; C, full set; D, patients with lung adenocarcinoma; E, patients with lung squamous cell carcinoma. The black horizontal lines indicate median values. P values were based on Kruskal–Wallis nonparametric test and Nemenyi test.

Fig 3: ROC curve analysis of CEA, SCCAg, Cyfra21‐1, CTAPIII/CXCL7, and biomarker combination in differentiating early stage NSCLC and controls. Panels A&B: CEA, SCCAg, Cyfra21‐1, CTAPIII/CXCL7, and biomarker combination in stage I NSCLC patients versus controls in the training (A) and test sets (B). Panels C&D: CEA, SCCAg, Cyfra21‐1, CTAPIII/CXCL7, and biomarker combination in stage Ia NSCLC patients versus controls in the training (C) and test sets (D).

Fig 4: Analysis of LDL-associated proteins from BC patients and healthy controls. A) Pattern of proteins enrichment on BC-associated LDL. LDL was isolated from plasma samples of BC patients or healthy women, and underwent proteomic analysis on a Q exactive HF orbitrap LC-MS/MS (Thermo scientific). Intensity values were logarithmized (Log2). Only proteins present in at least 10 / 40 samples were kept for statistical analysis. Signals that were originally 0 were imputed with fixed low value. Significantly changing proteins are marked red. Proteins are ordered by abundance relative to control (X-axis) and by difference significance (Y-axis). B) LDL of BC patients is enriched with CXCL4 and CXCL7. LDL and corresponding whole plasma samples from independent validation cohorts of healthy women and BC patients were analyzed by ELISA for measurement of CXCL4 or CXCL7 in BC patients as compared to healthy controls. Statistical significance was calculated using two-sided t-test and SEM. * (p < 0.05), ** (p < 0.01), *** (p < 0.001)